Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004)

Cardiff Oncology, Inc. announced that the first patient was dosed in its randomized first-line Phase II trial, for patients with RAS-mutated metastatic colorectal cancer.